Sea King Biology: HW130 injections receive a notice of approval for clinical trials of the drug.

Drug Basics Drug Name: HW130 Dosage Form: Injection Application: Clinical Trial Acceptance Number: CXHL2000365 Notice No: 2020LP00590 Review Conclusion: According to the People's Republic of China Drug The Administration Law and relevant provisions, after examination, on August 10, 2020, accepted HW130 injection with a strong solution in line with the relevant requirements of drug registration, agreed to carry out a clinical trial of advanced malignant solid tumor, multiple myeloma.
HW130 injection is a new type of tumor vascular blocker independently developed by Hai wang Pharmaceutical Research Institute and with independent intellectual property rights.
Through comprehensive preclinical studies, HW130 injection has significant effects of tumor vascular damage and significantly reduced tumor treatment patient mortality, significantly improving the clinical benefits of comprehensive tumor therapy;
project has been granted patents for compound inventions in China and the United States.
similar drugs at home and abroad are at different stages of preclinical and clinical research.
HW130 injection was approved for Phase I human clinical trials in the United States in January 2020.
.